These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 28377741)
1. Adenosine A Yin SB; Zhang XG; Chen S; Yang WT; Zheng XW; Zheng GQ Front Neurol; 2017; 8():88. PubMed ID: 28377741 [TBL] [Abstract][Full Text] [Related]
2. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Zhang K; Chammas C; Soghomonian JJ Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284 [TBL] [Abstract][Full Text] [Related]
3. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881 [TBL] [Abstract][Full Text] [Related]
4. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors. Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596 [TBL] [Abstract][Full Text] [Related]
5. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. Xiao D; Bastia E; Xu YH; Benn CL; Cha JH; Peterson TS; Chen JF; Schwarzschild MA J Neurosci; 2006 Dec; 26(52):13548-55. PubMed ID: 17192438 [TBL] [Abstract][Full Text] [Related]
6. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice. Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752 [TBL] [Abstract][Full Text] [Related]
7. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Carta AR; Pinna A; Cauli O; Morelli M Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048 [TBL] [Abstract][Full Text] [Related]
8. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model. Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664 [TBL] [Abstract][Full Text] [Related]
9. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
10. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Morin N; Morissette M; Grégoire L; Di Paolo T Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458 [TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632 [TBL] [Abstract][Full Text] [Related]
12. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021 [TBL] [Abstract][Full Text] [Related]
13. Dopamine-Induced Changes in Gα Morigaki R; Okita S; Goto S Front Cell Neurosci; 2017; 11():26. PubMed ID: 28239340 [TBL] [Abstract][Full Text] [Related]
14. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Ravenscroft P; Chalon S; Brotchie JM; Crossman AR Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317 [TBL] [Abstract][Full Text] [Related]
15. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359 [TBL] [Abstract][Full Text] [Related]
16. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Cenci MA; Lee CS; Björklund A Eur J Neurosci; 1998 Aug; 10(8):2694-706. PubMed ID: 9767399 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103 [TBL] [Abstract][Full Text] [Related]
18. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Carta AR; Pinna A; Tronci E; Morelli M Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008 [TBL] [Abstract][Full Text] [Related]
19. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Kobylecki C; Crossman AR; Ravenscroft P Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800 [TBL] [Abstract][Full Text] [Related]
20. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677 [No Abstract] [Full Text] [Related] [Next] [New Search]